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In type 1 diabetes, the appearance of islet autoantibodies indicates the onset of islet auto-
immunity, often many years before clinical symptoms arise. While T cells play a major role in
the destruction of pancreatic beta cells, molecular underpinnings promoting aberrant T cell
activation remain poorly understood. Here, we show that during islet autoimmunity an
miR142-3p/Tet2/Foxp3 axis interferes with the efficient induction of regulatory T (Treg)
cells, resulting in impaired Treg stability in mouse and human. Specifically, we demonstrate
that miR142-3p is induced in islet autoimmunity and that its inhibition enhances Treg
induction and stability, leading to reduced islet autoimmunity in non-obese diabetic mice.
Using various cellular and molecular approaches we identify Tet2 as a direct target of
miR142-3p, thereby linking high miR142-3p levels to epigenetic remodeling in Tregs. These
findings offer a mechanistic model where during islet autoimmunity miR142-3p/Tet2-medi-
ated Treg instability contributes to autoimmune activation and progression.
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Type 1 diabetes (T1D) results from a breakdown ofimmunological self-tolerance to the insulin-producing isletbeta cells, and consequently their destruction by auto-
reactive T cells1. The incidence of T1D is increasing worldwide,
especially in young children2. Longitudinal studies of individuals
at risk for developing T1D show that the disease progresses
through distinct identifiable stages prior to the onset of clinical
symptoms3,4. The appearance of multiple islet autoantibodies
indicates the onset of islet autoimmunity (pre-T1D), which can
occur years before clinical symptoms arise3. Despite ongoing
research efforts, the molecular mechanisms underlying the onset
of islet autoimmunity and progression to clinical diabetes remain
poorly understood.
Recent analyses have focused on the specific roles of different T
cell subsets during the presymptomatic stage of T1D and their
contribution to immune activation and autoimmunity5,6. High
frequencies of insulin-specific Tregs were associated with a slow
progression from islet autoimmunity to clinical T1D in children,
suggesting a crucial role for regulatory T cells (Tregs) in delaying
or possibly preventing the progression of islet autoimmunity7.
Tregs are key players for the maintenance of peripheral immune
tolerance, and defects in Treg induction and function are
important contributors to autoimmune disorders like T1D8–10.
Tregs are characterized by the expression of CD4, CD25, and the
transcription factor Foxp3, which is required for their develop-
ment and function11,12. The efficient induction of Foxp3+ Tregs
from naive CD4+ T cells can be achieved by the application of a
strong-agonistic T cell receptor (TCR) ligand under sub-
immunogenic conditions10,13–15. Mutations in the FOXP3 gene
have deleterious consequences, leading to autoimmune pheno-
types in both mice (scurfy mice) and humans (IPEX—immuno-
dysregulation, polyendocrinopathy, enteropathy, X-linked
syndrome), highlighting the crucial role of Foxp3 for Treg
function16,17.
Epigenetic mechanisms such as altered DNA methylation
patterns are a critical factor in the pathogenesis of several auto-
immune diseases18–20. The Foxp3 gene itself is subject to changes
in DNA methylation, controlling gene activity by altering the
accessibility of the DNA to transcription factors21,22. The hypo-
methylated state of four “conserved noncoding sequences” (CNS)
within the Foxp3 locus ensures proper Foxp3 expression in
Tregs23–25. In particular, the CNS2 is a critical regulator of long-
term stability of Foxp3 expression, and consequently the Treg
phenotype: The CNS2 element is completely demethylated in
Tregs but fully methylated in conventional T cells and in vitro-
induced Tregs23,25–27.
The establishment of hypomethylated regions is dependent
on three members of the “ten eleven translocation” (Tet)
family, Tet1, Tet2, and Tet328,29. These enzymes are capable of
oxidizing 5-methylcytosine (5mC) to 5-hydroxymethylcytosine
(5hmC), which is an intermediate of DNA demethylation30,31.
The Tet genes are critical for the differentiation of CD4+ T cells
in mice32 and humans33, as well as Treg homeostasis and
function34–36. Despite these insights, the molecular mechan-
isms that can regulate Tet gene expression in CD4+ T cells
remain incompletely understood. Moreover, it is unknown
whether aberrant Tet activity can impair Treg homeostasis
during islet autoimmunity.
MicroRNAs (miRNAs) critically contribute to immune func-
tion and homeostasis5,6,37–40. Although these studies provide
considerable insight into the role of miRNAs in immune home-
ostasis, their direct targets and affected signaling pathways remain
poorly understood, especially in human T cells. In particular, a
direct link between miRNA dysregulation and impaired Treg
induction in the context of the onset of autoimmunity has not
been reported yet.
Here, we identify a miRNA/Tet2 axis as a direct component of
Treg regulation. We propose that aberrant miR142-3p expression
in CD4+ T cells acting via Tet2 repression functions as one
mechanism by which dysregulated DNA methylation at the
Foxp3 locus mediates impaired Treg homeostasis, and conse-
quently contributes to autoimmune activation.
Results
miR142-3p is highly abundant in RISC of human CD4+
T cells. While profiles of total miRNA abundance in T cells have
been reported previously41, none have determined which miR-
NAs are actively engaged in mRNA regulation, and which
mRNAs are specifically targeted. Therefore, we performed high-
throughput sequencing of RNA isolated by crosslinking immu-
noprecipitation (HITS-CLIP) analysis of miRNAs and mRNA
fragments present in the RNA-induced silencing complex (RISC)
of human CD4+ T cells, following immunoprecipitation with an
antibody against Argonaute 2 (Fig. 1a). Mapping of the sequen-
cing reads to the human genome identified 271 unique miRNAs
as present within the RISC in human CD4+ T cells and 7829
mRNA targets. The analysis of our sequencing libraries showed
that miRNA binding occurs at comparable levels at the 3′ UTR
and the coding sequence of the mRNA target (Fig. 1b), with only
a slight preference for the 3′ UTR (Fig. 1c). This is in contrast to
earlier findings, suggesting that the binding happens pre-
ferentially at the 3′ UTR42.
The ten most abundant miRNAs in the RISC of human CD4+
T cells are shown in Fig. 1d. The abundance of individual
miRNAs in the RISC varied greatly and miR142-3p was the most
abundant active miRNA. Gene ontology analysis of the 500 most
targeted mRNAs showed a significant enrichment of biological
processes associated with immune activation, such as “T cell
signaling” and “T cell activation” (Fig. 1e).
Increased miR142-3p levels in islet autoimmunity and T1D. A
critical question is whether the abundance of individual miRNAs
is linked to the activation of islet autoimmunity. Therefore, in a
further set of experiments we isolated the miRNA fraction from
activated CD4+ T cells (CD4+CD3+CD45RA−CD45RO+CD127
+CD25intermediate; Supplementary Fig. 1a) of children with and
without islet autoimmunity to screen for differentially expressed
miRNAs by high-throughput sequencing. We identified multiple
differentially expressed miRNAs, with both down- and upregu-
lation of up to tenfold (Supplementary Fig. 2). One of the miR-
NAs specifically upregulated in activated CD4+ T cells from
children with ongoing islet autoimmunity was miR142-3p, with a
fold change of about 2 (Fig. 1f). The differential expression of
miR142-3p was validated by quantitative polymerase chain
reaction (qPCR) analysis of activated CD4+ T cells isolated from
peripheral blood of individuals without T1D and with recent
onset of T1D (Fig. 1g). Interestingly, we found that activated
T cells (CD4+CD25−CD44high; Supplementary Fig. 1b) in non-
obese diabetic (NOD) mice, a well-established model of T1D43,44,
with recent development of insulin autoantibodies (IAA) also
showed elevated levels of miR142-3p expression compared to
IAA− littermates (Fig. 1h). Furthermore, we analyzed an existing
mRNA sequencing dataset of individuals with ongoing islet
autoimmunity and healthy controls6 for differential expression of
predicted miR142-3p targets45. The majority of the predicted
miR142-3p targets was downregulated in CD4+ T cells of indi-
viduals with ongoing islet autoimmunity (Supplementary Fig. 3),
supporting the important role of this miRNA for the activation of
T-cell-specific islet autoimmunity.
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Inhibition of miR142-3p improves Treg induction in vitro.
Having established that miR142-3p is induced in CD4+ T cells
during onset of islet autoimmunity in both mice and human, we
next investigated the potential specific contribution of this
miRNA to autoimmune activation. We recently showed that
insulin-specific Tregs are significantly less abundant in children
with recent onset of islet autoimmunity7. We wondered if the
differentially expressed miR142-3p might interfere with Treg
induction from naive T cells, thereby promoting autoimmune
activation and progression. To this end, we performed in vitro
Treg induction assays using subimmunogenic stimulation of naive
CD4+ T cells (CD4+CD25−CD44−; Supplementary Fig. 4a)7,46
from NOD mice, with recent onset of islet autoimmunity. Treg
induction capacity of naive CD4+ T cells from NOD mice sig-
nificantly decreased with the onset of IAA+ autoimmunity
(Fig. 2a). Next, we performed murine in vitro Treg induction
experiments in the presence of miR142-3p mimics or miR142-3p
inhibitors (a representative flow cytometry staining is shown in
Fig. 2b and Supplementary Fig. 5a). Increasing miR142-3p
activity in the presence of a mimic significantly reduced Treg
induction efficacy using naive CD4+ T cells from non-
autoimmune prone BALB/c mice (Fig. 2c), resembling the
reduced Treg induction efficacy in IAA+ NOD mice. Con-
cordantly, blocking miR142-3p activity with a highly potent
inhibitor significantly increased Treg induction (Fig. 2c).
The high efficacy and specificity of the miRNA inhibitor was
demonstrated in several independent experimental settings. First,
the inhibitor reduced miR142-3p abundance by >99% after 3 h of
incubation (Supplementary Fig. 6a). Second, application of the
miRNA inhibitor significantly derepressed luciferase activity of a
miR142-3p activity sensor plasmid in Jurkat T cells (Supplemen-
tary Fig. 6b). Third, the inhibitor increased mRNA abundance of
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Fig. 1 miR142-3p is highly abundant in CD4+ T cells and upregulated in islet autoimmunity. a Schematic illustration of the HITS-CLIP technique.
b Average read coverage of RISC-associated mRNA fragments over a standardized mRNA as revealed by HITS CLIP. Dashed lines show the average levels.
CDS, coding sequence. c The outer pie shows the average size of the regions. The inner pie indicates the proportion of RISC-associated mRNA fragments
found in each section. d The ten most abundant RISC associated miRNAs in human CD4+ T cells, as revealed by HITS-CLIP. e Significantly enriched gene
ontology (GO) biological processes in target genes of RISC associated miRNAs in human CD4+ T cells, as revealed by HITS CLIP. f Levels of miR142-3p in
activated CD4+ T cells isolated from peripheral blood of children with and without islet autoimmunity, as revealed by miRNA sequencing of four pooled
samples per group. g Levels of miR142-3p in activated CD4+ T cells isolated from peripheral blood of children without T1D and with recent onset of T1D, as
revealed by qPCR normalized to 5s rRNA, n≥ 5. h Levels of miR142-3p in activated CD4+ T cells isolated from lymph nodes of NOD mice with and without
islet autoimmunity, as revealed by qPCR normalized to 5s rRNA. n= 6. One data point represents one subject. Experiments were performed in three
technical replicates per subject. Data are presented as means ± s.e.m., Student’s t-test, *P < 0.05, and **P < 0.01. The source data are provided as a Source
Data file.
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Tgfbr1 and ATG16L1, two established target genes of miR142-
3p47,48, after 6 h (Supplementary Fig. 6c, d).
Modulating miR142-3p activity by a mimic or inhibitor
likewise decreased or enhanced Treg induction efficacy, respec-
tively with naive CD4+ T cells from NOD mice that had not yet
developed IAA (Fig. 2d). Importantly, inhibiting miR142-3p
resulted in a significant improvement of Treg induction using
NOD mice with recent development of IAA+ autoimmunity
(Fig. 2e), while no significant changes in Treg induction potential
were observed using T cells from NOD mice with established
T1D (Fig. 2f).
Next, to assess the relevance of miR142-3p activity for human
Treg induction, we used naive CD4+ T cells (CD4+CD3+
CD45RA+CD45RO−CD127+CD25−; Supplementary Fig. 4b)
from individuals without islet autoimmunity, with recent onset
of T1D, and with established T1D. Comparing these groups
without miR142-3p modulation, we identified an overall reduc-
tion of Treg induction efficacy compared to healthy individuals
(Fig. 3a), as observed previously6. In naive CD4+ T cells from
subjects without islet autoimmunity, the miR142-3p mimic
significantly reduced the frequency of induced Tregs, while the
inhibition of miR142-3p improved Treg induction efficacy
(Fig. 3c), just as we had observed in the mouse model (a
representative flow cytometry staining is shown in Fig. 3b and
Supplementary Fig. 5b).
Increasing miR142-3p activity did not further reduce Treg
induction efficacy in naive CD4+ T cells from children with
recent onset of T1D (Fig. 3d) or individuals with established T1D
(Fig. 3e), presumably because miR142-3p levels were already
saturated in these cells. However, in both groups the inhibition of
miR142-3p resulted in significantly higher frequencies of induced
Tregs (Fig. 3d, e). These findings suggest that high levels of
miR142-3p limit in vitro Treg induction efficacy during islet
autoimmunity and T1D in humans and mice, while miR142-3p
inhibition was able to restore this impairment.
Inhibition of miR142-3p improves Treg stability. Having
demonstrated that the inhibition of miR-142-3p improves murine
and human Treg induction efficacy in vitro, we asked whether
this improvement was accompanied by increased Treg stability.
To assess phenotypic stability, we performed in vitro Treg
induction assays as before and subsequently restimulated the
induced Tregs for 30 h, both in the presence of the miR142-3p
inhibitor or a control inhibitor (Fig. 4a). Remarkably, the addition
of the miR142-3p inhibitor during restimulation resulted in a
significantly higher maintenance of the Treg phenotype, as evi-
denced by high levels of Foxp3 and CD25 (Fig. 4b). There were
no significant differences in cell viability and Ki67 expression
after Treg induction or restimulation, excluding altered cell sur-
vival or proliferation as a contributing factor (Supplementary
Fig. 7a–c). Thus, the beneficial effect of miR142-3p inhibition on
Treg induction efficacy is accompanied by an increased stability
of the Treg phenotype.
T cell activation changes Foxp3 CNS2 DNA methylation. To
dissect the mechanism underlying the miR142-3p effect, we
analyzed the methylation status of the Foxp3 gene at the con-
served CNS2, as this epigenetic mark is a key player in regulating
the Foxp3 locus. First, we employed high-resolution melting PCR
and pyrosequencing to determine the methylation status of the
Foxp3 CNS2 in in vitro-induced Tregs in the human and the
murine systems. Although in vitro-induced human Tregs exhibit
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Fig. 2 Inhibition of miR142-3p improves murine Treg induction in vitro. a In vitro Treg induction assays using limited TCR stimulation of naive CD4+
T cells isolated from lymph nodes of NOD mice with different stages of autoimmunity, as revealed by flow cytometry. n= 20 for IAA− and IAA+; n= 5 for
diabetic. b Representative flow cytometry plots for in vitro Treg induction assays in presence of a miR142-3p inhibitor and a control inhibitor, respectively,
using naive CD4+ T cells isolated from lymph nodes of BALB/c mice. c In vitro Treg induction assays in presence of a miR142-3p mimic and a miR142-3p
inhibitor, respectively, using naive CD4+ T cells isolated from lymph nodes of BALB/c mice, as revealed by flow cytometry, n= 8. d–f In vitro Treg
induction assays in presence of a miR142-3p mimic and a miR142-3p inhibitor, respectively, using naive CD4+ T cells isolated from lymph nodes of NOD
mice with different stages of autoimmunity, as revealed by flow cytometry, n= 5. One data point represents one subject. Experiments were performed in
three technical replicates per subject. Data are presented as box-and-whisker plots with mean, 25% percentile, 75% percentile, minimum and maximum
values. a Ordinary one-way ANOVA, Tukey’s multiple comparisons test. c–f Student’s t-test, *P < 0.05, **P < 0.01, and ***P < 0.001. The source data are
provided as a Source Data file.
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subimmunogenic TCR stimulation results in higher stability of
induced Tregs7. To capture potential methylation dynamics
during the early phase of murine and human Treg induction from
naive CD4+ T cells, we analyzed Treg markers and Foxp3 CNS2
methylation as early as 12 h following TCR stimulation. We
observed cells expressing Treg markers, especially high levels of
Foxp3, with an increase over time as shown for 12 and 18 h
in Fig. 4c (murine: CD4+CD25hiFoxp3hi) and Fig. 4e (human:
CD4+CD127loCD25hiFoxp3hi).
The DNA methylation analysis of cells with a Foxp3hi Treg
phenotype in this early phase of Treg induction showed a clear
dynamic in Foxp3 CNS2 methylation, which are only partially
captured by the in vitro differentiation system. Thus, initial
Treg induction from naive CD4+ T cells causes rapid CNS2
demethylation (Fig. 4d, f) and Foxp3 activation as expected.
However, longer culture leads to methylation at the CNS2,
likely a result of the culture conditions. Of note, the
demethylation was restricted to cells showing a Foxp3hi Treg
phenotype, while no changes in CNS2 methylation were
observed in Foxp3− cells (Supplementary Fig. 8a–d). These
results support the notion that the initial demethylation of
CNS2 is linked to the expression of Foxp3 and its downstream
targets, and is not solely the effect of TCR stimulation on cell
proliferation.
miR142-3p targets Tet2, a modulator of DNA methylation.
Inhibition of miR142-3p increases Treg induction and stability
in vitro, and this process is accompanied by a very rapid deme-
thylation of the crucial Foxp3 CNS2. Therefore, we hypothesized
that miR142-3p targets critical components in the DNA deme-
thylation machinery. We scanned predicted target genes of
miR142-3p45 and the mRNA targets that were associated with the
RISC in human CD4+ T cells (Fig. 1) for genes that can be
involved in demethylation. One interesting candidate was TET2,
which contains two predicted miR142-3p-binding sites in the 3′
UTR45 and exhibited multiple RISC footprints as shown by the
respective mRNA fragments aligned to the TET2 transcript
(Supplementary Fig. 9). The presence of TET2 mRNA fragments
in RISC footprints of the HITS-CLIP data indicated that TET2 is
targeted by miRNAs. In addition, the predicted miR142-3p-
binding sites pointed to an involvement of this miRNA in TET2
regulation.
To dissect if Tet2 links high miR142-3p levels to the regulation
of Treg induction efficacy and stability, we analyzed Tet2 gene
expression during the early phase of Treg induction in vitro from
BALB/c naive CD4+ T cells. We observed a strong increase in
Tet2 mRNA levels after 3 h of TCR stimulation, followed by a
decrease to baseline levels or below after 6 h (Fig. 5a). The
activation of Tet2 upon TCR stimulation of naive CD4+ T cells
was also reflected on the protein level, with increased protein
levels after 6 h and an additional increase after 12 h (Fig. 5c; a
representative flow cytometry staining including controls is
shown in Supplementary Fig. 10a). Thus, the kinetics of Tet2
accumulation are consistent with a role for Tet2 in Foxp3
demethylation.
In order to provide further support for Tet2 as a direct target of
miR142-3p, we performed Treg induction experiments using
naive CD4+ T cells from BALB/c mice in the presence of the
miR142-3p inhibitor or control inhibitor, and analyzed Tet2
mRNA and protein expression. Of note, inhibition of miR142-3p
resulted in significantly higher Tet2 mRNA levels after 6 h of TCR
stimulation (Fig. 5b), and increased Tet2 protein abundance after
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Fig. 3 Inhibition of miR142-3p improves human Treg induction in vitro. a In vitro Treg induction assays using limited TCR stimulation of naive CD4+
T cells isolated from peripheral blood of human subjects with different stages of T1D, as revealed by flow cytometry. n= 22 for no T1D n= 8 for recent onset
and long-term T1D. b Representative flow cytometry plots for in vitro Treg induction assays in presence of a miR142-3p inhibitor and a control inhibitor,
respectively, using naive CD4+ T cells isolated from human peripheral blood. c–e In vitro Treg induction assays in presence of a miR142-3p mimic and a
miR142-3p inhibitor, respectively, using naive CD4+ T cells isolated from human peripheral blood, as revealed by flow cytometry, (c) no autoimmunity n= 6
for mimic n= 16 for inhibitor, (d) recent onset of type 1 diabetes n= 5, (e) long-term type 1 diabetes n= 4. One data point represents one subject.
Experiments were performed in three technical replicates per subject. Data are presented as box-and-whisker plots with mean, 25% percentile, 75%
percentile, minimum and maximum values. a Ordinary one-way ANOVA, Tukey’s multiple comparisons test. c–e Student’s t-test, *P < 0.05, **P < 0.01, and
***P < 0.001. The source data are provided as a Source Data file.
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expression was also dynamic following T cell activation there was
no significant effect of miR142-3p inhibition, supporting the
notion that miR142-3p specifically targets Tet2 (Supplementary
Fig. 11a, b).
Moreover, a miR142-3p mimic induced a significant reduction
in luciferase activity in HEK-293 cells transfected with a wild-type
TET2 3′ UTR reporter construct while there was no effect of the
mimic in cells transfected with a reporter construct containing
the TET2 3′ UTR with mutated miR142-3p-binding sites (Fig. 5e,
Supplementary Fig. 12a). These results support the notion that
miR142-3p specifically targets Tet2.
Loss-of-function models confirm Tet2 as a miR142 target. In
addition, we used two loss-of-function models to mechanistically
validate Tet2 as a direct target of miR142-3p: Given the broad
role of Tet2 in various cell types, we first used the non-
hematopoietic 3T3 fibroblast cell line, which was previously
shown to lack miR142-3p expression almost completely49 (Sup-
plementary Fig. 12b). As a second approach, we dissected the
miR142-3p/Tet2 axis using T cells from miR142 knockout
(miR142−/−) mice50 (Supplementary Fig. 12c).
Specifically, we transfected 3T3 fibroblasts with a miR142-3p
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Fig. 4 miR142-3p inhibition improves stability of in vitro-induced Tregs. a Procedure and representative flow cytometry plots of restimulation
experiments in presence of a miR142-3p inhibitor and a control inhibitor, respectively, using Tregs previously induced from naive CD4+ T cells isolated
from lymph nodes of BALB/c Foxp3GFP reporter mice. b Quantification of restimulation experiments as described in a, as revealed by flow cytometry, n=
5. c Representative flow cytometry plot indicating CD4+CD25+Foxp3+ Tregs after 12 and 18 h of TCR stimulation of naive CD4+ T cells isolated from
lymph nodes of BALB/c mice. d Methylation of four CpG sites in the murine Foxp3 CNS2 of CD4+CD25+Foxp3+ Tregs after 0, 12, 18, and 36 h of
subimmunogenic TCR stimulation of naive CD4+ T cells isolated from lymph nodes of BALB/c mice, as revealed by pyrosequencing, n= 6.
e Representative flow cytometry plot indicating CD4+CD127−CD25+Foxp3+ Tregs after 12 and 18 h of TCR stimulation of human naive CD4+ T cells.
f Methylation of eight CpG sites in the human Foxp3 CNS2 of CD4+CD127-CD25+Foxp3+ Tregs after 0, 12, 18, and 36 h of subimmunogenic TCR
stimulation of naive CD4+ T cells isolated from human peripheral blood, as revealed by pyrosequencing, n= 6. One data point represents one subject.
Experiments were performed in two (d, f) or three (b) technical replicates per subject. Data are presented as box-and-whisker plots with mean, 25%
percentile, 75% percentile, minimum and maximum values or as means ± s.e.m., b Student’s t-test. (d, f) Ordinary one-way ANOVA, Tukey’s multiple
comparisons test. *P < 0.05, **P < 0.01, and ***P < 0.001. The source data are provided as a Source Data file.
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the absence of endogenous miR142-3p expression. The introduc-
tion of miR142-3p expression in these cells following mimic
application resulted in a significant decrease of Tet2 mRNA levels
(Fig. 5f). To further strengthen the mechanistic molecular
evidence for the direct miR142-3p/Tet2 relationship, we
used T cells from miR142 knockout animals. Stimulation of
CD4+ T cells from miR142 knockout mice demonstrated
significantly higher Tet2 mRNA levels when compared to
T cells from miR142 competent mice (Fig. 5g). The direct
targeting of Tet2 by miR142 was also validated on the protein
level (a representative flow cytometry staining is shown in
Supplementary Fig. 10b). Specifically, T cells from miR142-












































































































































































































































































































































































Fig. 5 miR142-3p targets methylcytosine dioxygenase Tet2. a Levels of Tet2 mRNA after TCR stimulation of CD4+ T cells isolated from lymph nodes of
BALB/c mice, as revealed by qPCR normalized to Histone mRNA, n≥ 8. b Levels of Tet2 mRNA after TCR stimulation of CD4+ T cells as described in a, in
presence of miR142-3p inhibitor, as revealed by qPCR normalized to Histone mRNA, n= 5. c Tet2 protein abundance after TCR stimulation of CD4+ T cells
as described in a, as revealed by flow cytometry, n= 5. d Tet2 protein abundance after TCR stimulation of CD4+ T cells as described in a, in presence of
miR142-3p inhibitor, as revealed by flow cytometry, n= 6. e Normalized luciferase activity of HEK-293 cells cotransfected with miR142-3p mimic and wild-
type TET2 3′UTR reporter construct, n= 4. f Levels of Tet2 mRNA in 3T3 fibroblasts transfected with miR142-3p mimic, as revealed by qPCR normalized to
Histone mRNA, n= 6. g Levels of Tet2 mRNA after TCR stimulation of CD4+ T cells isolated from lymph nodes of miR142+/+ and miR142-/- mice, as
revealed by qPCR normalized to Histone mRNA, n= 4. h Tet2 protein abundance after limited TCR stimulation of CD4+ T cells as described in g, as
revealed by flow cytometry, n= 6. i In vitro Treg induction in presence of Tet2 siRNA, using naive CD4+ T cells isolated from lymph nodes of BALB/c mice,
as revealed by flow cytometry, n= 6. j In vitro Treg induction in presence of Tet2 siRNA, using naive CD4+ T cells isolated from human peripheral blood, as
revealed by flow cytometry, n= 4. One data point represents one subject. Experiments were performed in three technical replicates per subject. Data are
presented as box-and-whisker plots with mean, 25% percentile, 75% percentile, minimum and maximum values or as means ± s.e.m. (a, c, e) Ordinary
one-way ANOVA, Tukey’s multiple comparisons test. (b, d, f–j) Student’s t-test, *P < 0.05, **P < 0.01, and ***P < 0.001. The source data are provided as a
Source Data file.
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deficient animals presented with significantly higher Tet2 protein
expression following TCR stimulation when compared to T cells
from miR142+/+ mice (Fig. 5h). Furthermore, we stimulated
CD4+ T cells from miR142 knockout mice in the presence of a
miR142-3p inhibitor or a control inhibitor in vitro. As expected,
the inhibitor did not increase mRNA abundance of Tet2 or the
established target genes of miR142-3p, Tgfbr1, and ATG16L1
(Supplementary Fig. 12d–f). These findings underline and
confirm the direct effect of the miR142-3p inhibitor in miR142
competent mice and provide compelling evidence for direct
targeting of Tet2 by miR142.
To directly test the importance of Tet2 for murine and human
Treg induction, we purified naive CD4+ T cells from BALB/c
mice and human subjects without T1D, and performed Tet2
knockdown experiments using a Tet2 short interfering RNA
(siRNA). Reduced Tet2 abundance during Treg induction
resulted in a significantly attenuated Treg induction efficacy in
both the murine and human setting (Fig. 5i, j). Taken together,
these results suggest a critical role for Tet2 in T cell activation and
Treg induction, and confirm the identification of Tet2 as an
important direct target of miR142-3p.
Islet autoimmunity changes Tet2 levels and CNS2 methylation.
Next, to investigate the relevance of these findings to islet auto-
immunity, we analyzed if the onset of islet autoimmunity alters
miR142-3p levels and Tet2 abundance to directly contribute to
impaired Treg induction. To this end, we compared IAA+ to
control, IAA− NOD mice. IAA+ NOD mice exhibited higher
miR142-3p levels in CD4+ T cells compared to IAA− mice
(Fig. 1h), which correlated with reduced protein abundance of its
target Tet2 (Fig. 6a). We confirmed the reduction in Tet2
abundance in CD4+T cells by immunofluorescence microscopy
of pancreatic cryosections from NOD mice with or without IAA+
autoimmunity, which revealed significantly reduced numbers of
pancreas-infiltrating CD3+Tet2+ T cells in IAA+ mice (Fig. 6b, c
and Supplementary Fig. 13a) despite an increase in the total
number of pancreas-infiltrating CD3+ T cells (Supplementary
Fig. 13b). Furthermore, immunofluorescence microscopy of
CD4+ T cells purified from human peripheral blood showed a
reduced abundance of CD3+Tet2+ T cells in subjects with recent
onset of T1D compared to subjects without T1D (Fig. 6d, e).
If our proposed miR142-3p/Tet2/Foxp3 axis indeed exists, one
would expect DNA methylation at the Foxp3 CNS2 to be altered
by islet autoimmunity accordingly. Therefore, we analyzed the
Foxp3 CNS2 methylation of Tregs from NOD mice with recent
development of IAAs, and also in children with recent onset of
T1D and compared them to controls without IAA/T1D. As
shown in Fig. 6f, g, all individual CpG sites within the CNS2 of
Tregs from individuals, whether mouse or humans, with islet
autoimmunity showed higher DNA methylation levels, and this
effect reached statistical significance at several sites. In addition,
analysis of the entire Foxp3 CNS2 region demonstrated
significantly increased DNA methylation (Fig. 6f, g).
To dissect the potential causative contribution of impaired
Treg stability in promoting autoimmune progression, we assessed
Foxp3 CNS2 DNA methylation in NOD mice <30 days of age
with a very early onset of IAA+ positivity. Of note, these very
young IAA+ NOD mice presented with distinctly increased
Foxp3 CNS2 DNA methylation when compared to nonautoim-
mune prone BALB/c mice (Supplementary Fig. 13c), supporting
the concept that early onset Treg instability can be involved in
promoting autoimmune activation and progression.
Since the composition of the Treg pool with regard to thymic-
derived and peripheral Tregs might have an effect on differential
Foxp3 CNS2 methylation, we analyzed Tregs isolated from
peripheral blood of human subjects without T1D and with recent
onset of T1D. The expression of Helios, which is a marker of
thymic-derived Tregs51, was not significantly different between
the two groups (Supplementary Fig. 13d). These results support a
direct link between miR142-3p levels, Tet2 expression, and Foxp3
CNS2 methylation affecting Treg induction and stability during
ongoing islet autoimmunity.
miR142-3p inhibitor improves NOD islet autoimmunity
in vivo. To address the pathological relevance of these findings
in vivo, we next analyzed the effect of miR142-3p inhibition in
NOD mice with ongoing IAA+ autoimmunity. We used an
established LNA-miRNA-inhibitor, which has been shown to
accumulate in tissues, including lymphoid tissues, when applied
systemically52 thereby facilitating miRNA silencing in vivo6,53.
The miR142-3p inhibitor was applied at 10 mg/kg, intraper-
itoneally (ip) every other day for 14 days. Using a fluorescently
labeled miR142-3p inhibitor, we confirmed the successful delivery
of the inhibitor to CD4+ T cells in relevant draining lymph
nodes, including liver-draining lymph nodes, mesenteric lymph
nodes, as well as pancreatic lymph nodes and directly in
pancreas-residing CD4+ T cells as assessed after 4 h (Supple-
mentary Fig. 14a) and 24 h (Supplementary Fig. 14b). In addition,
the successful delivery of the inhibitor to CD4+ T cells was also
demonstrated in lymph nodes at the end of the 14 days appli-
cation period (Supplementary Fig. 14c, d). Moreover, the effi-
ciency of the delivered miR142-3p inhibitor in pancreatic tissue
and local immune cells was validated by demonstrating increased
expression of Tgfbr1, a well-established target of miR142-3p47, in
pancreatic T cells (Supplementary Fig. 14e, f).
Of note, blockade of miR142-3p-reduced pancreatic T cell
infiltration as shown by histopathological analyses of pancreatic
sections (Fig. 7a, b). These effects of miR142-3p inhibition were
accompanied by reduced IAA levels (Fig. 7c), while blood glucose
levels or body mass were unaffected (Supplementary Fig. 15a, b).
Importantly, immunofluorescence analyses revealed significantly
enhanced frequencies of Foxp3+ Tregs within the pancreas
following blockade of miR142-3p in vivo (Fig. 7d, e and
Supplementary Fig. 15c). In addition and in line with a direct
targeting of Tet2 by miR142-3p its blockade in vivo resulted in a
significant increase in Tet2 expression in pancreatic T cells of
NOD mice (Fig. 7f, g). These results were accompanied by an
elevated Tet2 expression (Supplementary Fig. 15d) and a reduced
proliferation indicated by lower Ki67 expression (Supplementary
Fig. 15e) in peripheral T cells of miR142-3p inhibitor-treated
mice.
In order to directly link these observations with a modulation
of Treg stability, we next investigated the effects of in vivo
miR142-3p inhibition on Foxp3 CNS2 demethylation in Tregs.
To this end, we analyzed CNS2 methylation of Tregs from
pancreatic lymph nodes of inhibitor-treated IAA+ NOD mice. All
individual CpG sites within the CNS2 of miR142-3p inhibitor-
treated mice exhibited decreased DNA methylation, and this
effect reached statistical significance when the entire CNS2 region
was considered (Fig. 7h).
To confirm that the observed effects of miR142-3p inhibitor
application on Treg induction, stability and Tet2 in vivo were
directly mediated by reduced miR142-3p activity, we applied the
miR142-3p inhibitor to miR142 knockout mice. As expected, the
inhibitor had no effect on Treg frequency (Supplementary
Fig. 16a), Tet2 protein abundance (Supplementary Fig. 16b), or
Foxp3 CNS2 methylation (Supplementary Fig. 16c) in miR142-
deficient mice.
Finally, to assess a potential relevance of miR142-3p inhibition
in human T cells from an established T1D environment, we used
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peripheral blood mononuclear cells (PBMCs) from individuals
with T1D for a pilot experiment to reconstitute the murine major
histocompatibility complex II (MHCII) deficient, HLA-DQ8
transgenic NOD.Cg-Prkdcscid Il2rgtm1Wjl (NSG) mouse model7 for
the establishment of humanized mice. Application of a miR142-3p
inhibitor to these humanized NSG mice showed a trend toward
increased frequencies of peripheral CD127lowCD25hi Tregs and a
significant increase in Tet2 expression in pancreatic T cells
(Supplementary Fig. 17), suggesting that further dose titration or
daily application of the inhibitor might be required.
Discussion
The molecular underpinnings promoting both onset of auto-
immunity and the highly variable progression to clinically overt
T1D remain poorly understood. Recent studies have highlighted
miRNAs as crucial regulators of immune homeostasis, and sug-
gested that their dysregulation contributes to the onset of auto-
immunity and/or the progression to symptomatic T1D5,6,37–40. In
silico target prediction tools predicted a multitude of potential
targets, the relevance of which have remained unclear. The
identification of specific miRNAs that contribute to the onset of
autoimmunity and the identification of their relevant targets, and
downstream pathways will considerably advance our under-
standing of autoimmune activation and facilitate the development
of future intervention and prevention approaches.
Here, we identified increased levels of miR142-3p, which is the
most abundant active miRNA in the RISC of human CD4+
T cells, during the onset of islet autoimmunity and T1D in CD4+
T cells of mice and humans. We employed a combination of
various molecular and cellular approaches45,54–56, including
miR142-3p modulation and loss-of-function models, to identify
Tet2 as a relevant target of miR142-3p. Moreover, we provide
compelling evidence for a link of miR142-3p/Tet2 signaling to
impaired Treg homeostasis and function.
The onset of islet autoimmunity and T1D in mice or humans is






























NOD CD3+Tet2+ T cells
IAA– IAA+ No T1D Recent onset of T1D




















CD3+Tet2+ T cells in pancreata of NOD mice
Human CD4+ T cells
No T1D Recent onset of T1D



















































CpG1 CpG2 CpG3 CpG4 All CpGsCpG5 CpG6 CpG7 CpG8
* * * * ***
CD3/Tet2/DAPICD3/Tet2/DAPI
0 μm 50 0 μm 50
0 μm 750 μm 75
Fig. 6 Tet2 abundance and Foxp3 CNS2 methylation are changed in islet autoimmunity. a Ex vivo Tet2 protein abundance (median fluorescence
intensity) in CD4+ T cells isolated from pancreatic lymph nodes of NOD mice with and without islet autoantibodies, as revealed by flow cytometry, n= 5.
b Immunofluorescence staining for CD3 (green), Tet2 (red), and DAPI (blue) in pancreas cryosections of NOD mice with and without islet autoimmunity.
Scale bars: 50 µm. c Quantification of CD3+Tet2+ T cells per high-power field in samples from b, n= 12. d Immunofluorescence staining for CD3 (green),
Tet2 (red), and DAPI (blue) in cytospins of human CD4+ T cells isolated from peripheral blood of individuals with and without recent onset of T1D. Scale
bars: 75 µm. e Quantification of CD3+Tet2+ T cells per high-power field in samples from d, n= 6. f Methylation of the Foxp3 CNS2 (four CpG sites and
combination of all sites) in Tregs isolated from pancreatic lymph nodes of female NOD mice with and without autoimmunity, as revealed by
pyrosequencing, n= 6. g Methylation of the Foxp3 CNS2 (eight CpG sites and combination of all sites) in Tregs isolated from peripheral blood of male
human subjects with recent onset of T1D and healthy controls, as revealed by pyrosequencing, n= 8. One data point represents one subject/one high-
power field. Experiments were performed in two (f and g) or three (a) technical replicates per subject. Data are presented as box-and-whisker plots with
mean, 25% percentile, 75% percentile, minimum and maximum values or as means ± s.e.m. (f, g) Ordinary one-way ANOVA, Tukey’s multiple
comparisons test. (a, c, e) Student’s t-test, *P < 0.05, **P < 0.01, and ***P < 0.001. The source data are provided as a Source Data file.
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differentiated into Tregs in vitro. Critically, we could reproduce
this effect by subimmunogenic in vitro Treg induction assays in
the presence of a miR142-3p mimic, suggesting that the dysre-
gulation of miR142-3p indeed contributes to impaired Treg
induction. Conversely, the inhibition of miR142-3p during
in vitro Treg induction improved Treg induction efficacy and was
accompanied by enhanced Treg stability.
We proposed a miR142-3p/Tet2/Foxp3 axis as one possible
mechanism to explain increased Treg stability upon miR142-3p
inhibition. Bioinformatic prediction tools45 as well as cellular loss
function models and a broad set of molecular approaches,
including a TET2 3’UTR luciferase reporter assay revealed the
methylcytosine dioxygenase Tet2 as a direct target of miR142-3p.
Tet enzymes are involved in the control of Treg generation and
maintenance by active demethylation of the Foxp3 CNS227,36,
and overexpression of the Tet1 catalytic domain improves the
stability of Foxp3 expression in induced Tregs57. Here, we
document rapid demethylation of the Foxp3 CNS2 in the early
phase of the Treg induction, using highly naive CD4+T cells as
the starting population. This effect was absent in cells with low
levels of Foxp3, indicating that CNS2 demethylation does not
result from TCR stimulation per se. In line with these observa-
tions, we found Tet2 expression to be increased following TCR
stimulation. Importantly, the inhibition of miR142-3p in vitro
resulted in increased levels of Tet2 mRNA and protein, further
supporting the concept of Tet2 as a direct target of miR142-3p.
Given the key impact of Tet2 in a variety of cell types, we
analyzed the role of miR142-3p signaling in nonhematopoietic
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Fig. 7 miR142-3p inhibition improves murine islet autoimmunity in vivo. a Representative hematoxylin and eosin-stained pancreas cryosections from
IAA+ NOD mice treated with a miR142-3p inhibitor or control inhibitor for 14 days with 10mg/kg ip every other day. Scale bars: 100 µm. b Grading of
insulitis from mice treated as described in a, n= 3 per group. c IAA levels in serum of IAA+ NOD mice after treatment with a control inhibitor or a miR142-
3p inhibitor as described in a and revealed by ELISA. Data are shown as change from baseline, n= 3. d Immunofluorescent staining for CD3 (green), Foxp3
(red), Insulin (white), and DAPI (blue) in pancreas cryosections of IAA+ NOD mice treated with a miR142-3p inhibitor or control inhibitor as described in a.
Scale bars: 50 µm. e Quantification of CD3+Foxp3+ T cells per high-power field in samples from c, n= 14. f Immunofluorescent staining for CD3 (green),
Tet2 (red), and DAPI (blue) in pancreas cryosections of IAA+ NOD mice treated with a miR142-3p inhibitor or control inhibitor as described in a. Scale
bars: 50 µm. g Quantification of CD3+Tet2+ T cells per high-power field in samples from f, n≥ 7. h Methylation of the Foxp3 CNS2 (four CpG sites and
combination of all sites) in Tregs isolated from pancreatic lymph nodes of IAA+ NOD mice treated with a miR142-3p inhibitor or control inhibitor as
described in a and revealed by pyrosequencing. One data point represents one high-power field. Experiments were performed in two technical replicates
per subject (h). Data are presented as box-and-whisker plots with mean, 25% percentile, 75% percentile, minimum and maximum values or as means ± s.e.
m. h Ordinary one-way ANOVA, Tukey’s multiple comparisons test. (c, e, g) Student’s t-test, *P < 0.05, and **P < 0.01. The source data are provided as a
Source Data file.
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3T3 fibroblasts, which do not express miR142-3p endogenously.
Here, the gain-of-function experiment using the application of a
miR142-3p mimic caused a diminished Tet2 expression in line
with the biochemical and molecular findings, indicating a direct
miR142-3p/Tet2 axis. In addition, increased Tet2 mRNA and
protein levels of in vitro-activated T cells isolated from miR142−/−
compared to miR142 competent mice, provide compelling
mechanistic evidence for direct targeting of Tet2 by miR142-3p.
Furthermore, the diminished Treg induction efficacy in the
presence of a Tet2 siRNA provides additional conceptual support
for the functional relevance of the miR142-3p/Tet2 axis for
murine and human Treg induction, and homeostasis. The fact
that reducing Tet2 expression alone was sufficient to interfere
with Treg induction potential underscores the critical contribu-
tion of Tet2 when compared to previous studies, which employed
combined Tet targeting36.
From an immunopathological perspective, the analysis of
murine and human T cell samples with recent onset of auto-
immunity/T1D directly links Tet2 abundance and the methyla-
tion status of the Foxp3 CNS2 with islet autoimmunity in vivo.
Thus, in NOD mice with islet autoimmunity CD4+ T cells
express low levels of Tet2 and pancreas-resident Foxp3+ Tregs
were significantly reduced. Similarly, CD4+ T cells isolated from
peripheral blood of human subjects with recent onset of T1D
showed diminished Tet2 expression compared to subjects without
T1D. In addition, there was a significant increase in Foxp3 CNS2
methylation of Tregs upon onset of islet autoimmunity and in
T1D. These results further support our hypothesis that dysregu-
lated DNA methylation remodeling mediates impaired Treg
homeostasis and consequently can contribute to the promotion of
islet autoimmunity. Importantly, the increased Foxp3 CNS2 DNA
methylation in NOD mice <30 days of age with a very early onset
of autoimmunity suggests a potential causative role of miR142-
3p/Tet2 signaling in promoting autoimmune activation and
progression.
Of note, the in vivo inhibition of miR142-3p reduced murine
islet autoimmunity and islet autoantibody levels, while increasing
frequencies of both Foxp3+ Tregs and Tet2+ T cells in the
pancreas. These effects were accompanied by reduced methyla-
tion of the Foxp3 CNS2, suggesting that the observed effect of
miR142-3p inhibition is due to Tet2-mediated DNA demethyla-
tion and improved Treg stability. Moreover, the results of a pilot
experiment with humanized NSG mice reconstituted with
PBMCs from individuals with established T1D suggests that
miR142-3p inhibition might have a beneficial effect in improving
Treg homeostasis even in the context of established T1D. Future
studies, including dose titration and variations in application
duration will be necessary to validate these findings in Tregs in
the experimental setting of established T1D.
In conclusion, we identify a miR142-3p/Tet2/Foxp3 axis in
murine and human CD4+ T cells that during islet autoimmunity
interferes with the efficient induction of Tregs and leads to
impairments in Treg stability. These results offer a mechanistic
model where during islet autoimmunity miR142-3p/Tet2-medi-
ated Treg instability can contribute to autoimmune activation and
progression, and suggest that targeting miR142-3p could con-
tribute to the development of intervention strategies, aiming at
improved Treg induction and stability to interfere with islet
autoimmunity.
Methods
Human subjects. All human studies comply with the relevant ethical regulations
for work with human participants and all study participants gave written consent
prior to inclusion in the Munich Bioresource project (approval number #5049/11,
Technische Universität München, Munich, Germany). Venous blood was collected
using sodium heparin tubes and blood volumes were based on EU guidelines with a
maximal blood volume of 2.4 ml per kg of body weight. All subjects have been
already enrolled in the BABYDIAB study3,58,59 and the DiMelli study60 with the
documented age of T1D onset. Subjects have been stratified based on the presence
or absence of multiple islet autoantibodies and T1D. No islet autoimmunity and no
T1D: n= 6; median age at sampling= 8 years, IQR (interquartile range)= 6–12
years; all male. Recent onset of T1D: n= 10; median age at sampling= 4 years,
IQR= 3–5 years; median HbA1c= 8.9 mg/dl, IQR= 8.4–10.6 mg/dl; median time
from diagnosis to sampling= 7 days, IQR= 1–11 days; all male.
In vitro studies with primary human T cells. Freshly isolated human CD4+
T cells were cultured in X-Vivo15 Medium (Lonza) supplemented with 2 mM
glutamine, 100 U/ml human recombinant IL-2 (ReproTech), 50 U/ml penicillin, 50
mg/ml streptomycin (Sigma Aldrich), and 5% heat-inactivated human AB serum
(Invitrogen) at 37 °C in a humidified CO2 incubator. Cell culture-treated 96-well U
bottom plates were used (Bio-Greiner one).
Mice. CBy.PL(B6)-Thy1a/ScrJ (CD90.1 BALB/c), Balb/cByJ (CD90.2 BALB/c),
Balb/c.Cg-Foxp3tm2Tch/J (BALB/c Foxp3GFP), and NOD/ShiLtJ mice were
obtained from the Jackson Laboratory and NOD/ShiLtJ mice were stratified
according to their IAA status. Humanized mice, NOD.Cg-Prkdcscid H2-Ab1tm1Gru
Il2rgtm1Wjl Tg(HLA-DQA1,HLA-DQB1) 1Dv//Sz mice lack mouse MHC class II
and transgenically express human HLA-DQ8. These mice were obtained from and
developed by Dr. Leonard D. Shultz. To develop this stock, B10M-HLA-DQ8 mice
were kindly provided by Dr. Chella David61. The DQ8 transgene was backcrossed
for ten generations on the NSG strain background. The NSG-DQ8 mice were then
intercrossed with NSG mice lacking mouse MHC class II (NOD.Cg-Prkdcscid H2-
Ab1tm1Gru Il2rgtm1Wjl)62. miR142−/− mice were developed by excision of the
miR142 region in C57BL/6 N mouse embryonic stem cells50 and obtained from the
mouse facility of the German Center for Lung Research, Universities of Giessen
and Marburg (Mfd Diagnostics, Wendelsheim, Germany). When possible litter-
mate controls were used, otherwise age- and sex-matched mice. Mice were
maintained under specific pathogen-free conditions on 12-h/12-h light dark cycle
at 25 °C with ad libitum access to water and a standard diet at the animal facility of
Helmholtz Zentrum München, Munich, Germany according to guidelines estab-
lished by the Institutional Animal Committees, including all relevant ethical reg-
ulations for animal testing and research. Ethical approval for all mouse
experimentations has been received by the District Government of Upper Bavaria,
Munich, Germany (approval # ROB-55.2-2532.Vet_02-17-130).
In vitro studies with primary murine T cells. Freshly isolated murine CD4+
T cells were cultured in RPMI media (Gibco by life technologies) supplemented
with 10% FCS, 1 mM sodium pyruvate (Sigma Aldrich), 50 mM b-mercaptoethanol
(Amimed), 1× nonessential amino acids (Merck Millipore), 100 U/ml human
recombinant IL-2 (ReproTech), 100 U/ml penicillin, and 100 mg/ml streptomycin
(Sigma Aldrich) at 37 °C in an humidified CO2 incubator. Cell culture-treated 96-
well U bottom plates were used (Bio-Greiner one).
Murine insulin autoantibody assay. Levels of NOD IAA were measured with a
mouse high specificity/sensitivity competitive IAA assay in an enzyme-linked
immunosorbent assay (ELISA) format and sera from NOD mice. In brief, high-
binding 96-well plates (Costar) were coated with human recombinant insulin
(100 U/ml; Humulin; Lilly) overnight at 4 °C. Unspecific blocking was performed
with PBS containing 2% BSA for 2 h at room temperature. Preincubated NOD sera
(diluted 1:10) with or without insulin competition were added and incubated for
2 h at room temperature. After four wash steps, biotinylated antimouse IgG1
(Abcam), diluted 1:10,000 in PBS/BSA was added for 30 min at room temperature.
After washing horseradish peroxidase-labeled streptavidin was added for 15 min.
After five additional washing steps, TMB substrate solution was added (OptEIA
reagent set; BD). All samples were measured in duplicates with and without
competition using human insulin.
In a second approach, to determine levels of IAA in NOD mice, a Protein A/G
radiobinding assay based on 125I-labeled recombinant human insulin, was applied
as previously described59. Serum from C57Bl/6 mice was used as negative control.
Cell isolation. Human PBMCs were isolated from fresh venous blood by density
gradient centrifugation using Ficoll-Paque PLUS (GE Healthcare). CD4+ T cells
were purified from PBMCs by Magnetic Activated Cell Sorting (MACS) using CD4
microbeads (Miltenyi Biotec) following the manufacturer’s protocol.
Murine lymph nodes and spleens were passed through 70 μm cell strainers,
stained with a CD4-Biotin antibody (BD Bioscience) and MACS purified using
Streptavidin Microbeads (Miltenyi Biotec) following the manufacturer’s protocol.
Cell staining and sorting. To prevent unspecific signals, the isolated cells were
incubated with Fc-Block (Biolegend) and afterward with fluorochrome-labeled
antibodies for 30 min on ice in the dark. For FACS staining of human T cells the
following monoclonal antibodies were used: from BD Biosciences (San Jose, CA):
anti-CD25 APC (2A3), anti-CD45RO APC-H7 (UCHL1), anti-CD4 V500 (RPA-
T4), and anti-HLA-DR PerCP-Cy5.5 (L243); from Biolegend (San Diego, CA):
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anti-CD45RA FITC (HI100), anti-CD3 PerCP-Cy5.5 (HIT3a), anti-CD127 PE-Cy7
(A019D5), and anti-CD3 AlexaFluor700 (HIT3a); from eBioscience (San Diego,
CA): anti-FOXP3 PE (236 A/E7). For murine FACS staining, the following
monoclonal antibodies were used: from BD Biosciences (San Jose, CA): anti-CD4
Biotin (GK1.5); from Biolegend (San Diego, CA): CD25 PerCP-Cy5.5 (PC61) and
CD44 PE (IM7) Ki67 APC (16A8); from eBioscience (San Diego, CA): CD4
AlexaFluor700 (RM4-5), CD62L APC (MEL-14), and Foxp3 FITC (FJK-16s); from
Abiocode: Tet2 (10F1). After surface staining, the cells were fixed and permeabi-
lized using the Foxp3 Staining Buffer Kit (eBioscience) to enable the detection of
the intracellular abundance of Foxp3, Ki67, and Tet2. Cells were acquired on the
BD FACS Aria III cell sorting system using FACS Diva software with optimal
compensation and gain settings determined for each experiment based on
unstained and single-color stained samples. Doublets were excluded based on SSC-
A vs. SSC-W plots. Live cell populations were gated on the basis of cell side and
forward scatter, and the exclusion of cells positive for Sytox Blue (Life Technolo-
gies) or Fixable Viability Dye eFluor450 (ebioscience). Flow cytometry data were
analyzed using FlowJo software version 7.6.1 (TreeStar Inc., OR)
HITS-CLIP. Human CD4+ T cells were homogenized subjected to UV-crosslinking
three times at 400 mJ/cm² and extra RNA bound to the RISC complex was digested
with RNase T1. The Argonaute complex was then immunoprecipitated 2–4 h at
4 °C using the monoclonal Argonaute antibody 2A8. Phosphate from the pre-
cipitated complex was removed and a 5′-32P-labeled RL3 linker was attached. The
samples were separated by SDS-gel electrophoresis, transferred to a nitrocellulose
membrane and visualized by autoradiography. The desired area with the com-
plexed argonaute protein was cut and subjected to RNA extraction; afterward the 5′
RNA linker was ligated. In the following, RNAs were amplified by RT/PCR, the
resulting products were separated on agarose gel and two respective populations of
RNA (50–60 bp for small RNAs, 80–180 bp for mRNAs) extracted. After a re-PCR
with Solexa Fusion Primers the desired bands on an agarose gel (miRNA, 150 bps;
mRNA, smear ~200 bps) were again extracted, quality checked on an Agilent
Bioanalyzer.
HITS-CLIP—sequencing and alignment statistics. Two libraries, mRNA- and
miRNA-enriched, were sequenced to 100 bp on a HiSeq 2500. Two processing
pipelines were used. The first considered only the nonchimeric reads in that the
alignment program, bowtie, was looking for end-to-end alignments and did not
allow significant parts of the read to “dangle”. The second, applied to just the
mRNA library used STAR to align to the transcriptome and did allow dangling
ends. Dangling ends were then selected for lengths consistent with mature miRNAs
and aligned to miRNA hairpins.
HITS-CLIP—nonchimeric statistics. The nonchimeric pipeline trims adapter
sequence using a program written in the Kaestner lab63. There was some evidence
of double ligation due to the enrichment for chimeric reads. We trimmed adapters
from the 3′-end that (partially) match GTGTCAGTCACTTCCAG or
TGTCAGTCACTTCCAG. We kept sequences that were at least 16 bp long. After
trimming reads were aligned to the human genome, human RefSeq transcripts, and
human miRNA hairpin sequences using bowtie allowing for multiple alignments.
The mRNA library is enriched for long fragments, many of which will span introns
or are chimeric, so the genomic alignment rate is lower than the miRNA library.
RefSeq alignment for the mRNA fraction is also lower due to the chimeric frag-
ments. The miRNA fraction of the miRNA library is relatively high. Roughly, 81
million mRNA fragments and 68 million miRNA reads were used in the following
steps. We identified locations of RISC occupancy on RefSeq transcripts as follows:
the alignments were processed to count the number of times each position in the
transcripts occurred at the start of an alignment. Then these weighted positions
were clustered (from heavy to light) into bins of 10 bp to create the 5′-ends of the
RISC complex footprints. We identified 265,406 footprints on 28,693 transcripts.
To quantify miRNA occupancy in the RISC complex, we counted the number of
read that overlapped with the annotated locations (miRbase v20) on the miRNA
hairpins (Table 1).
miRNA expression analysis (NGS). For high-throughput sequencing of miRNAs,
total RNA of four-pooled samples of activated CD4+ T cells from children with or
without ongoing islet autoimmunity was extracted using the miRNeasy Micro Kit
(Qiagen). cDNA libraries were obtained using the NEBnext Multiplex Small RNA
Library Prep Set (New England Biolabs) according to the manufacturer’s protocol.
Sequencing was performed on a HiSeq2000 (Illumina) with 50 bp single end reads
using Illumina reagents and following the manufacturer’s instructions.
NGS data processing and statistical analysis. Unwanted adaptor sequences were
trimmed from small RNA reads using BTrim64 and quality of sequencing was
assessed for trimmed read data with a mean phred quality score of 38, referring to a
base call accuracy of 99.99%. Read data was filtered of unwanted RNA fragments
by mapping on rRNA, tRNA, snRNA, and snoRNA sequences obtained from the
Rfam database using bowtie65. Remaining reads were then mapped on mature
human miRNA sequences obtained from mirBase (release 20)66 and summed up to
read count lists using SAMTools. mRNA read data was processed comparably
without unnecessary trimming and filtering. Raw read data was mapped on the
human genome (build 37.2) using a gapped alignment for paired end data with
bowtie267. Finally, read count lists were created by HTSeqcount 4768. Differential
expression of miRNA was evaluated using DESeq69, handling size factor correction
and normalization.
Isolation and analysis of miRNAs. SmallRNAs/miRNAs were isolated using the
miRNeasy Micro Kit (Qiagen). RNA concentration and purity were determined by
nanodrop (Epoch, Biotech). For cDNA synthesis, the Universal cDNA Synthesis
Kit II (Exiqon) was used according to the instructions. qPCR was performed using
the ExiLENT SYBR Green PCR Master Mix (Exiqon) in combination with miR-
CURY LNA primers for miR142-3p. For normalization, miRCURY LNA primers
for the housekeeper 5s rRNA were used (Exiqon). For primer sequences see
Supplementary Table 1. The reaction was performed on a CFX96 real time system
(Biorad).
Isolation and analysis of mRNAs. mRNAs were isolated using the miRNeasy
Micro Kit (Qiagen). cDNA synthesis was performed with the iScript cDNA
Synthesis Kit (Biorad). For qPCR the SsoFast Evagreen Supermix (Biorad) and self-
designed gene-specific primers were used. For normalization, the primers for the
housekeeping gene Histone were used. For primer sequences see Supplementary
Table 1. The reactions were performed on a CFX96 Real Time System (Biorad).
Methylation analysis. Up to 2000 CD4+ T cells were subjected to a combined
sample lysis and bisulfite conversion using the EZ DNA Methylation-Direct Kit
(Zymo Research) according to the manufacturer’s instructions. For bias-controlled
quantitative methylation analysis, a combination of methylation-sensitive high
resolution melting (MS–HRM) and subsequent pyrosequencing was performed.
Utilizing the PyroMark Assay Design Software 2.0 (Qiagen), PCR primers and the
according sequencing primers were designed to cover the area of differential
methylation in the first Foxp3 intron initially reported by Baron et al.23. For primer
sequences see Supplementary Table 1. MS–HRM was performed using the Sensi-
FAST HRM Kit (Bioline) and the CFX96 real time system (Biorad). Pyrosequen-
cing was performed on the PyroMark Q24 system (Qiagen) using PyroMark Gold
Q24 Reagents (Qiagen) and following the manufacturer’s instructions.
Human in vitro Treg induction by limited TCR stimulation. Human naive CD4+
T cells (CD3+, CD4+, CD45RA+, CD45RO−, CD127+ and CD25−) were sorted
with the BD FACS Aria III for purity and cultured (10,000 or 100,000 / well) in a
96-well plate precoated with 5 μg/ml anti-CD3 and 5 μg/ml anti-CD28 antibody
with additional IL2 (100 U/ml). Limited TCR stimulation was achieved by pipetting
the cells into uncoated wells, after 18 h, where they were cultured for additional 36
h without further TCR stimulation. Treg induction efficiency was measured using
flow cytometry by analyzing Foxp3 expression in CD25+CD127−CD4+ T cells.
Murine in vitro Treg induction by limited TCR stimulation. Murine naive CD4+
T cells (CD4+, CD25−, and CD44−) were sorted with the BD FACS Aria III for
purity and cultured (10,000 or 100,000 / well) in a 96-well plate pre-coated with
5 μg/ml anti-CD3 and 5 μg/ml anti-CD28 antibody with additional IL2 (100 U/ml).
Limited TCR stimulation was achieved by pipetting the cells into uncoated wells
after 18 h, where they were cultured for additional 36 h without further TCR sti-
mulation. Treg induction was measured by flow cytometry by analyzing Foxp3
expression in CD25+CD4+ T cells.
Nanoparticles. The nanoparticles were prepared by an emulsion-diffusion-
evaporation method, first described by Kumar et al.70 with slight modifications.
The emulsion was prepared using a Harvard syringe pump for controlled dropping
speed. Particles were passed through a sterile filter after preparation. The
fluorescent-labeled particles were prepared with a poly(lactic-co-glycolic acid)
(PLGA−) fluoresceinamine (FA) conjugate. Particles were characterized with
Dynamic light scattering (Zetasizer Nano ZS, Malvern). Chitosan PLGA nano-
particles and FA-labeled nanoparticles (in brackets) had a mean hydrodynamic
Table 1
Library Raw reads Trimmed reads Genomic (%) RefSeq (%) RefSeq N miRNA (%) miRNA N
mRNA 236,827,218 205,594,509 45.8 39.6 81,389,124 15.5
miRNA 172,094,624 140,008,888 79.1 74.6 48.6 67,980,650
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diameter of 146.7 ± 0.8 nm (152.8 ± 1.2 nm), polydispersity index 0.068 ± 0.009
(0.056 ± 0.007) and a zeta potential of +29.6 ± 0.3 mV (+29.6 ± 0.7 mV).
Application of miR142-3p inhibitor and mimic. Chitosan-coated PLGA nano-
particles were loaded with the inhibitor or mimic (miRCURY LNA miRNA
mimic/inhibitor, Exiqon) at a weight ratio of nanoparticles:inhibitor/mimic of 50:1
and incubated at room temperature for 30 min with gentle shaking. The loaded
nanoparticles were added to the wells of a polyclonal Treg induction assay at a final
concentration of 6 pmol/well (human) or 9 pmol/well (murine). As a control,
nanoparticles loaded with miRNA mimic/inhibitor controls (Exiqon) were added
to the cultures. For inhibitor/mimic sequences see Supplementary Table 1.
3′ UTR luciferase reporter assay. HEK-293 cells were cotransfected with a dual
luciferase plasmid containing the wild-type or mutated full-length 3′ UTR from
human TET2 (RefSeq NM_001127208.2) and a miR142-3p mimic (10 pmol/well)
at 10,000 cells per well in a 96-well plate using Lipofectamine 3000 (Thermo Fisher
Scientific) for 24 h. Luminescence was measured with the Dual Luciferase Reporter
Assay Kit (Promega) following the manufacturer’s protocol. The ratio of Firefly
over Renilla luminescence was determined and compared to the transfection
control. The mutations were introduced in the predicted miR142-3p-binding
sites45 in the TET2 3′ UTR (position 4135-4141 and 5392-5398) using site-directed
mutagenesis by PCR. For primer sequences see Supplementary Table 1.
miR142-3p activity assay. A miR142-3p activity sensor plasmid was constructed
by inserting a double-stranded oligonucleotide containing the miR142-3p target
sequences (miR142-3p reverse complement, with a central bulged mismatch) into
the 3′ UTR of a dual luciferase reporter plasmid. Jurkat T cells were cotransfected
with the miR142-3p activity sensor plasmid and a miR142-3p inhibitor (5 pmol/
well) at 50,000 cells per well in a 96-well plate, using Attractene transfection
reagent (Qiagen) for 24 h. Luminescence was measured with the Dual Luciferase
Reporter Assay Kit (Promega) following the manufacturer’s protocol. The ratio of
Firefly over Renilla luminescence was determined and compared to the transfection
control.
Application of Tet2 siRNA. Tet2 siRNA (Silencer Select Pre-Designed siRNA
Tet2, Ambion) or control siRNA (Silencer Select Negative control no.1, Ambion)
were combined with siRfficient transfection reagent (MBL Life Science) following
the manufacturer’s protocol. A total of 20 pmol siRNA were added to murine and
human Treg induction assays. For siRNA information see Supplementary Table 1.
3T3 fibroblasts. 3T3 fibroblasts were seeded in 96-well plates at a density of
10,000 cells/well. After 24 h the cells were transfected with 10 pmol of miR142-3p
mimic or control mimic using Lipofectamine RNAiMAX Reagent, following the
manufacturer’s instructions.
Restimulation assay. After in vitro Treg induction using naive CD4+ T cells from
BALB/c Foxp3GFP reporter mice in the presence of a miR142-3p inhibitor,
Foxp3+CD25+CD4+ Tregs were sort-purified. The Tregs were then stimulated for
30 h with anti-CD3 and anti-CD28 antibodies in the presence of a miR142-3p
inhibitor or a control inhibitor. Maintenance of the Treg phenotype was measured
by flow cytometry analysis of Foxp3 expression in CD25+CD4+ T cells.
Engraftment of NSG mice with human PBMCs. Murine MHCII deficient, HLA-
DQ8 transgenic NOD.Cg-Prkdcscid Il2rgtm1Wjl (NSG) mice were reconstituted with
PBMCs from an HLA-DQ8+ donor with T1D. A total of 5 × 104 PBMCs per
mouse were injected intravenously in 50 ml PBS into the retro orbital sinus without
prior conditioning by irradiation or busulfan treatment. To avoid sex incompat-
ibilities, the sex of the NSG-HLA-DQ8 mice for reconstitution was chosen in
accordance with the blood donor.
In vivo miR142-3p inhibitor application. A miR142-3p inhibitor (Inhibitor Probe
mmu-miR-142-3p, Exiqon) was injected i.p. into IAA+ NOD mice or NSG
humanized mice at 10 mg/kg every other day for 14 days. On day 15 Treg fre-
quencies were analyzed in lymph nodes. CD25highFoxp3high Tregs were sort-
purified for methylation analysis. Pancreata were embedded for cryosections and
analysis of pancreas pathology. For miRNA inhibitor localization experiments, a
FAM-labeled miR142-3p inhibitor (mmu-miR-142-3p inhibitor 5′FAM, Qiagen)
was injected i.p. into BALB/c or NSG-humanized mice at 10 or 20 mg/kg. The
FAM-labeled miR142-3p inhibitor was detected via flow cytometry after 4 h, 24 h
or at the end of an application period of 14 days every other day.
Immunofluorescence staining of NOD pancreata. Immunofluorescence staining
was carried out after acetone fixation, permeabilization, and blocking with Avidin/
Protein blocking together with 5% goat serum using rabbit-anti-mouse insulin
antibodies (Cell Signaling, 1:100) and donkey-anti-rabbitAlexaFluor647 antibodies
(Dianova, 1:400). For CD3 staining, arm.hamster anti-mouse antibodies (BD, 1:50)
were used, followed by goat-anti-arm.hamster antibodies conjugated with
Dylight488 (Dianova, 1:100). For Tet2 staining, rabbit-anti-Tet2 antibodies
(ABclonal, clone A5682, 1:25) was used with biotinylated horse-anti-rabbit anti-
bodies (Vector, 1:100) combined with SADylight 549. For Foxp3 staining, cells were
incubated with rat-anti-mouse Foxp3 antibodies (eBioscience, clone FJK-16s, 1:50)
and biotinylated goat anti-rabbit (BD), combined with SADylight 549. Nuclei were
counterstained with DAPI (Diavona). For Tgfbr1 staining, rat-anti-mouse/human
Tgfbr1 antibodies (R&D, clone 141231, 1:25) was used, followed with biotinylated
goat-anti-rat antibodies (1:250) combined with SADylight 549 (Dianova, 1:200).
Negative control slides were incubated with secondary antibodies. Cells were
analyzed by confocal microscopy (Zeiss LSM700).
Histopathology of NOD pancreata. Pancreata of NOD mice were embedded with
Tissue-Tek O.C.T. Compound and frozen on dry ice. Serial sections were stained
with hematoxylin and eosin. Insulitis scoring was performed as follows: 0: intact
islets/no lesions; 1: peri-islet infiltrates; 2: < 25% islet destruction; 3: > 25% islet
destruction; 4: complete islet destruction. Investigators were blinded for group
allocations.
Statistical analysis. Results are presented as mean and s.e.m or as percentages,
where appropriate. For normally distributed data, Student’s t-test for unpaired
values was used to compare means between independent groups and the Student’s
t-test for paired values was used to compare values for the same sample or subject
tested under different conditions. For multiple testing, ordinary one-way analysis
of variance (ANOVA) and Tukey’s multiple comparisons test were used. For all
tests, a two-tailed P value of < 0.05 was considered to be significant. Statistical
significance is shown as *= P < 0.05; **= P < 0.01; and ***= P < 0.001, or not
significant (NS) P > 0.05. Analyses were performed using the program GraphPad
Prism 7 (La Jolla, CA).
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
The authors declare that all data supporting the findings of the study are available within
the article and its Supplementary Material or from the corresponding author upon
reasonable request. The source data underlying Fig. 1g, h, 2a, c–f, 3a, c–e, 4b, d, f, 5a–j,
6a, c, e–g, 7b, c, e, g, h and Supplementary Figures 3, 6a–d, 7a–c, 8b, d, 11a, b, 12a–f,
13b–d, 14d, f, 15a, b, 16a–c, and 17c are provided as a Source Data file. HITS-CLIP
library sequencing data have been deposited to GEO database under the accession
number GSE124264. miRNA sequencing data have been deposited to GEO database
under the accession number GSE140064.
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